Mahesh N Samtani

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi Simple pharmacometric tools for oral anti-diabetic drug development: competitive landscape for oral non-insulin therapies in type 2 diabetes
    Mahesh N Samtani
    Clinical Pharmacology Advanced PK PD Modeling and Simulation, Johnson and Johnson Pharmaceutical Research and Development, Raritan, New Jersey 08869, USA
    Biopharm Drug Dispos 31:162-77. 2010
  2. ncbi An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative
    Mahesh N Samtani
    Clinical Pharmacology, Advanced PK PD Modeling and Simulation, Johnson and Johnson Pharmaceutical R and D, 920 Route 202, PRD 2723, Raritan, NJ 08869 e mail
    J Clin Pharmacol 52:629-44. 2012
  3. ncbi Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjects
    Mahesh N Samtani
    Clinical Pharmacology, Advanced PK PD Modeling and Simulation, Johnson and Johnson Pharmaceutical R and D, 920 Route 202, PRD 2723, Raritan, NJ 08869, USA
    J Clin Pharmacol 49:336-50. 2009
  4. ncbi Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic
    Mahesh N Samtani
    Clinical Pharmacology, Advanced PK PD Modeling and Simulation, Johnson and Johnson Pharmaceutical Research and Development, LLC, 920 Route 202, PRD 2723, Raritan, NJ 08869, USA
    Clin Pharmacokinet 48:585-600. 2009
  5. ncbi Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data
    Mahesh N Samtani
    Johnson Johnson Pharmaceutical Research Development, L L C, Raritan, NJ, USA
    CNS Drugs 25:829-45. 2011
  6. ncbi Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients
    Mahesh N Samtani
    Clinical Pharmacology, Advanced PK PD Modeling and Simulation, Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, NJ 08560, USA
    Antimicrob Agents Chemother 54:2360-4. 2010
  7. ncbi Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infections
    Holly Kimko
    Johnson and Johnson Pharmaceutical Research and Development, LLC, 920 Route 202 South, Raritan, NJ 08869, USA
    Antimicrob Agents Chemother 53:3371-4. 2009
  8. ncbi Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients
    Partha Nandy
    Clinical Pharmacology, Advanced PK PD Modeling and Simulation, Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, NJ 08560, USA
    Antimicrob Agents Chemother 54:2354-9. 2010

Detail Information

Publications8

  1. ncbi Simple pharmacometric tools for oral anti-diabetic drug development: competitive landscape for oral non-insulin therapies in type 2 diabetes
    Mahesh N Samtani
    Clinical Pharmacology Advanced PK PD Modeling and Simulation, Johnson and Johnson Pharmaceutical Research and Development, Raritan, New Jersey 08869, USA
    Biopharm Drug Dispos 31:162-77. 2010
    ..8% or more and possess safety profiles similar to newer anti-diabetic agents. Thus, this study proposes a suite of simple yet powerful tools to guide type-2-diabetes drug development...
  2. ncbi An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative
    Mahesh N Samtani
    Clinical Pharmacology, Advanced PK PD Modeling and Simulation, Johnson and Johnson Pharmaceutical R and D, 920 Route 202, PRD 2723, Raritan, NJ 08869 e mail
    J Clin Pharmacol 52:629-44. 2012
    ....
  3. ncbi Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjects
    Mahesh N Samtani
    Clinical Pharmacology, Advanced PK PD Modeling and Simulation, Johnson and Johnson Pharmaceutical R and D, 920 Route 202, PRD 2723, Raritan, NJ 08869, USA
    J Clin Pharmacol 49:336-50. 2009
    ....
  4. ncbi Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic
    Mahesh N Samtani
    Clinical Pharmacology, Advanced PK PD Modeling and Simulation, Johnson and Johnson Pharmaceutical Research and Development, LLC, 920 Route 202, PRD 2723, Raritan, NJ 08869, USA
    Clin Pharmacokinet 48:585-600. 2009
    ..To characterize the population pharmacokinetics of paliperidone after intramuscular administration of its long-acting palmitate ester at various doses and at two different injection sites (deltoid and gluteal muscle)...
  5. ncbi Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data
    Mahesh N Samtani
    Johnson Johnson Pharmaceutical Research Development, L L C, Raritan, NJ, USA
    CNS Drugs 25:829-45. 2011
    ..Population PK modelling presented in this review has helped provide practical guidance for administering this novel LAI antipsychotic...
  6. ncbi Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients
    Mahesh N Samtani
    Clinical Pharmacology, Advanced PK PD Modeling and Simulation, Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, NJ 08560, USA
    Antimicrob Agents Chemother 54:2360-4. 2010
    ..Results of pharmacokinetics/pharmacodynamics (PK/PD) modeling can guide dose optimization, thereby potentially increasing the clinical efficacy of doripenem against serious Gram-negative bacterial infections...
  7. ncbi Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infections
    Holly Kimko
    Johnson and Johnson Pharmaceutical Research and Development, LLC, 920 Route 202 South, Raritan, NJ 08869, USA
    Antimicrob Agents Chemother 53:3371-4. 2009
    ..A ceftobiprole regimen of 500 mg every 8 h as a 2-h infusion has a high probability of achieving a target of >or=30 or >or=50% T>MIC for patients with cSSSI due to gram-positive and gram-negative pathogens...
  8. ncbi Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients
    Partha Nandy
    Clinical Pharmacology, Advanced PK PD Modeling and Simulation, Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, NJ 08560, USA
    Antimicrob Agents Chemother 54:2354-9. 2010
    ....